Eli Lilly and Company (NYSE:LLY) Shares Climb 3.8% – Here’s What Happened

Eli Lilly and Company (NYSE:LLY) traded up 3.8% during mid-day trading on Wednesday. The stock traded as high as $1,213.82 and last traded at $1,211.1430. Approximately 377,091 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 2,939,294 shares. The stock had previously closed at $1,166.51.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong obesity and diabetes momentum: RBC expects Lilly could raise its full-year revenue outlook, supported by continued sales of Zepbound and other cardiometabolic products. Retatrutide is also viewed as a potentially larger future growth driver, with investor attention likely to intensify ahead of the company’s October 29 earnings report. RBC expects Lilly to raise revenue outlook
• Positive Sentiment: Favorable earnings expectations: Erste Group raised its FY2026 EPS estimate to $36.55 from $36.45 and its FY2027 estimate to $47.30. Analysts are also anticipating continued earnings growth in the upcoming third-quarter report. Eli Lilly earnings preview
• Positive Sentiment: Pipeline expansion: Lilly’s collaboration with Prelude Therapeutics will test an experimental breast-cancer drug in combination with established therapies, adding to its oncology pipeline. Broader industry cancer-drug spending is projected to exceed $400 billion by 2028, supporting long-term opportunity. Prelude clinical trial collaboration
• Neutral Sentiment: Valuation remains a key debate: Commentary highlights Lilly’s exceptional growth and potential undervaluation relative to its outlook, but the stock trades at a premium multiple, making execution and pipeline results important.
• Negative Sentiment: Clinical risks remain: A study of a combination involving Zepbound produced greater weight loss but substantially higher discontinuation rates, raising questions about tolerability and commercial adoption. Zepbound combination study

Analyst Ratings Changes

LLY has been the subject of several research analyst reports. Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, August 26th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Leerink Partners boosted their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Finally, Morgan Stanley increased their price objective on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,313.43.

Eli Lilly and Company Trading Up 3.9%

The stock’s fifty day moving average price is $1,176.60 and its 200 day moving average price is $1,102.08. The stock has a market cap of $1.14 trillion, a P/E ratio of 40.65, a PEG ratio of 1.52 and a beta of 0.46. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts expect that Eli Lilly and Company will post 34.79 earnings per share for the current year.

Insider Transactions at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 over the last three months. 0.14% of the stock is currently owned by company insiders.

Institutional Trading of Eli Lilly and Company

A number of hedge funds and other institutional investors have recently modified their holdings of LLY. First Citizens Bank & Trust Co. lifted its position in shares of Eli Lilly and Company by 22.3% in the third quarter. First Citizens Bank & Trust Co. now owns 38,512 shares of the company’s stock valued at $44,561,000 after acquiring an additional 7,019 shares in the last quarter. Focus Financial Network Inc. lifted its stake in Eli Lilly and Company by 9.0% in the 3rd quarter. Focus Financial Network Inc. now owns 7,646 shares of the company’s stock worth $8,847,000 after purchasing an additional 632 shares in the last quarter. Citrine Capital LLC grew its position in shares of Eli Lilly and Company by 8.6% during the third quarter. Citrine Capital LLC now owns 239 shares of the company’s stock valued at $277,000 after purchasing an additional 19 shares in the last quarter. Liberty Atlantic Advisors LLC purchased a new position in Eli Lilly and Company during the 3rd quarter valued at approximately $245,000. Finally, XY Planning Network Inc. boosted its position in shares of Eli Lilly and Company by 60.4% during the 3rd quarter. XY Planning Network Inc. now owns 730 shares of the company’s stock valued at $845,000 after acquiring an additional 275 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.